Accepted for Publication: October 27, 2011.
Published Online: February 20, 2012. doi:10.1001/archdermatol.2011.2561
Author Contributions: All authors had full access to all the data in the study and take responsibility for the integrity and accuracy of the data analysis. Study concept and design: Atanaskova Mesinkovska, Tellez, Molina, Honari, Sood, and Taylor. Acquisition of data: Atanaskova Mesinkovska, Tellez, Molina, and Taylor. Analysis and interpretation of data: Atanaskova Mesinkovska, Tellez, Honari, Barsoum, and Taylor. Drafting of the manuscript: Atanaskova Mesinkovska, Tellez, and Molina. Critical revision of the manuscript for important intellectual content: Atanaskova Mesinkovska, Honari, Sood, Barsoum, and Taylor. Administrative, technical, and material support: Atanaskova Mesinkovska and Taylor. Study supervision: Honari, Sood, Barsoum, and Taylor.
Financial Disclosure: Dr Taylor has served as a consultant for the National Institute for Occupational Safety and Health; Betco, Inc; Shire Pharmaceuticals, plc; Novartis; Procter & Gamble; AMA Press; and the Consumer Product Safety Commission. He has received honoraria from the American Academy of Dermatology; Chinese Society of Dermatology; HMP Communications; Medicis Pharmaceutical Corporation; Hermal Pharmaceutical Laboratories Germany; BASF; UnitedHealthcare; Regent Medical Ltd; Uni-Tech Communications; Watson Pharmaceuticals; WebMD; and HOB Biotech/SmartPractice. Dr Taylor has had stock ownership in Amgen (sold in 2008); Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson; Keithley Instruments (sold in 2006); Merck & Co, Inc; Medco Health Solutions; Wyeth Pharmaceuticals (sold in 2009); and Renovo, plc. He has received grants from Guidant and Shire. His department is an investigator for Amgen; Astellas Pharma; Biogen Idec; Bristol-Myers Squibb; Eli Lilly and Company; Genentech; Lexington International; Johnson & Johnson; Novartis AG; Pfizer, Inc; Procter & Gamble; Centocor; Sovay Pharmaceuticals; and Wyeth Pharmaceuticals. Dr Barsoum has served as a consultant for Stryker Orthopaedics; Wright Medical Technology, Inc; and Shukla Medical. He is a member of the speakers' bureau for Stryker Orthopaedics. Dr Barsoum has stock ownership or options in OtisMed Corporation; Custom Arthroplasty Solutions; and Custom Orthopaedic Solutions, Inc. He has received grants from Stryker Orthopaedics; Zimmer; Salient Surgical Technologies; CoolSystems, Inc; and Orthovita, Inc. He has filed and received multiple patents. Dr Barsoum receives royalties from Stryker Orthopaedics; Exactech, Inc; Wright Medical Technology; and Shukla Medical. None of the financial relationships listed for Drs Taylor and Barsoum are directly relevant to the subject matter of this article.
Additional Contributions: We are indebted to James Bena, MS, from the Cleveland Clinic Foundation for assistance with statistical analysis. (Mr Bena received compensation for this assistance.)